Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5230-5239

  Derer, Stefanie ^a   Bauer, Philip ^a   Lohse, Stefan ^a   Scheel, Andreas H ^b   Berger, Sven ^a   Kellner, Christian ^a   Peipp, Matthias ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Pathologie Nordhessen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL STRAIN BHK; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; STABLE TRANSFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MONOCYTES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84869777228     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202037     Document Type: Article

References (51)

1. Topalian, S. L., G. J. Weiner, and D. M. Pardoll. 2011. Cancer immunotherapy comes of age. J. Clin. Oncol. 29: 4828-4836.
2. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-53.
3. Nimmerjahn, F., and J. V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19: 239-245. (Pubitemid 46356962)
4. Macor, P., and F. Tedesco. 2007. Complement as effector system in cancer immunotherapy. Immunol. Lett. 111: 6-13. (Pubitemid 47017475)
5. Gelderman, K. A., S. Tomlinson, G. D. Ross, and A. Gorter. 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25: 158-164. (Pubitemid 38249490)
6. Scott, A. M., J. D. Wolchok, and L. J. Old. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12: 278-287.
7. Reichert, J. M., and E. Dhimolea. 2012. The future of antibodies as cancer drugs. Drug Discov. Today 17: 954-963.
8. Weiner, L. M., J. C. Murray, and C. W. Shuptrine. 2012. Antibody-based immunotherapy of cancer. Cell 148: 1081-1084.
9. Mendelsohn, J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20(18, Suppl.)1S-13S.
10. Ciardiello, F., and G. Tortora. 2008. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358: 1160-1174.
11. Bardelli, A., and S. Siena. 2010. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28: 1254-1261.
12. Allegra, C. J., J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton, and R. L. Schilsky. 2009. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27: 2091-2096.
13. Derer, S., S. Berger, M. Schlaeth, T. Schneider-Merck, K. Klausz, S. Lohse, M. B. Overdijk, M. Dechant, C. Kellner, I. Nagelmeier, et al. 2012. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. Neoplasia 14: 190-205.
14. Pirker, R., J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. de Marinis, W. E. Eberhardt, L. Paz-Ares, S. Störkel, et al. 2012. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13: 33-42.
15. Olive, M., S. Untawale, R. J. Coffey, M. J. Siciliano, D. M. Wildrick, H. Fritsche, S. Pathak, L. M. Cherry, M. Blick, P. Lointier, et al. 1993. Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell. Dev. Biol. 29A: 239-248. (Pubitemid 23123714)
16. Ruifrok, A. C., and D. A. Johnston. 2001. Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 23: 291-299. (Pubitemid 32762920)
17. Schlaeth, M., S. Berger, S. Derer, K. Klausz, S. Lohse, M. Dechant, G. A. Lazar, T. Schneider-Merck, M. Peipp, and T. Valerius. 2010. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci. 101: 1080-1088.
18. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
19. Beyer, T., S. Lohse, S. Berger, M. Peipp, T. Valerius, and M. Dechant. 2009. Serum-free production and purification of chimeric IgA antibodies. J. Immunol. Methods 346: 26-37.
20. Dechant, M., W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. Parren, J. G. van de Winkel, and T. Valerius. 2008. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68: 4998-5003.
21. Idusogie, E. E., P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166: 2571-2575. (Pubitemid 32173494)
22. Pegram, M. D., G. Pauletti, and D. J. Slamon. 1998. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52: 65-77. (Pubitemid 29056086)
23. Sauter, G., J. Lee, J. M. Bartlett, D. J. Slamon, and M. F. Press. 2009. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27: 1323-1333.
24. Lewis, G. D., I. Figari, B. Fendly, W. L. Wong, P. Carter, C. Gorman, and H. M. Shepard. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37: 255-263. (Pubitemid 23300507)
25. van Meerten, T., R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12: 4027-4035. (Pubitemid 44078090)
26. van Meerten, T., H. Rozemuller, S. Hol, P. Moerer, M. Zwart, A. Hagenbeek, W. J. Mackus, P. W. Parren, J. G. van de Winkel, S. B. Ebeling, and A. C. Martens. 2010. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica 95: 2063-2071.
27. Chung, K. Y., J. Shia, N. E. Kemeny, M. Shah, G. K. Schwartz, A. Tse, A. Hamilton, D. Pan, D. Schrag, L. Schwartz, et al. 2005. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23: 1803-1810. (Pubitemid 46211358)
28. O'Byrne, K. J., U. Gatzemeier, I. Bondarenko, C. Barrios, C. Eschbach, U. M. Martens, Y. Hotko, C. Kortsik, L. Paz-Ares, J. R. Pereira, et al. 2011. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 12: 795-805.
29. Patel, D., X. Guo, S. Ng, M. Melchior, P. Balderes, D. Burtrum, K. Persaud, X. Luna, D. L. Ludwig, and X. Kang. 2010. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum. Antibodies 19: 89-99.
30. Kurai, J., H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, T. Sako, H. Touge, H. Makino, M. Takata, M. Miyata, et al. 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13: 1552-1561. (Pubitemid 46450447)
31. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502. (Pubitemid 351560518)
32. Peipp, M., M. Dechant, and T. Valerius. 2008. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr. Opin. Immunol. 20: 436-443.
33. Klausz, K., S. Berger, J. J. Lammerts van Bueren, S. Derer, S. Lohse, M. Dechant, J. G. van de Winkel, M. Peipp, P. W. Parren, and T. Valerius. 2011. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 102: 1761-1768.
34. Hsu, Y. F., D. Ajona, L. Corrales, J. M. Lopez-Picazo, A. Gurpide, L. M. Montuenga, and R. Pio. 2010. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol. Cancer 9: 139.
35. Overdijk, M. B., S. Verploegen, J. H. van den Brakel, J. J. Lammerts van Bueren, T. Vink, J. G. van de Winkel, P. W. Parren, and W. K. Bleeker. 2011. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J. Immunol. 187: 3383-3390.
36. Zhang, W., M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H. M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25: 3712-3718. (Pubitemid 47372612)
37. Bibeau, F., E. Lopez-Crapez, F. Di Fiore, S. Thezenas, M. Ychou, F. Blanchard, A. Lamy, F. Penault-Llorca, T. Frébourg, P. Michel, et al. 2009. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27: 1122-1129.
38. Rodríguez, J., R. Zarate, E. Bandres, V. Boni, A. Hernández, J. J. Sola, B. Honorato, N. Bitarte, and J. García-Foncillas. 2012. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur. J. Cancer 48: 1774-1780.
39. Maréchal, R., J. De Schutter, N. Nagy, P. Demetter, A. Lemmers, J. Devière, I. Salmon, S. Tejpar, and J. L. Van Laethem. 2010. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer 10: 340.
40. Woof, J. M., and D. R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4: 89-99. (Pubitemid 38209203)
41. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555. (Pubitemid 35223554)
42. Algars, A., H. Irjala, S. Vaittinen, H. Huhtinen, J. Sundström, M. Salmi, R. Ristamäki, and S. Jalkanen. 2012. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int. J. Cancer 131: 864-873.
43. Sica, A., T. Schioppa, A. Mantovani, and P. Allavena. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42: 717-727.
44. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
45. Tiroch, K., B. Stockmeyer, C. Frank, and T. Valerius. 2002. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J. Immunol. 168: 3275-3282. (Pubitemid 34250388)
46. Würflein, D., M. Dechant, B. Stockmeyer, A. L. Tutt, P. Hu, R. Repp, J. R. Kalden, J. G. van de Winkel, A. L. Epstein, T. Valerius, et al. 1998. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res. 58: 3051-3058. (Pubitemid 28335086)
47. Zalevsky, J., I. W. Leung, S. Karki, S. Y. Chu, E. A. Zhukovsky, J. R. Desjarlais, D. F. Carmichael, and C. E. Lawrence. 2009. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113: 3735-3743.
48. Lutterbuese, R., T. Raum, R. Kischel, P. Hoffmann, S. Mangold, B. Rattel, M. Friedrich, O. Thomas, G. Lorenczewski, D. Rau, et al. 2010. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc. Natl. Acad. Sci. USA 107: 12605-12610.
49. Koefoed, K., L. Steinaa, J. N. Søderberg, I. Kjær, H. J. Jacobsen, P. J. Meijer, J. S. Haurum, A. Jensen, M. Kragh, P. S. Andersen, and M. W. Pedersen. 2011. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3: 584-595.
50. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
51. Paz-Ares, L. G., C. Gomez-Roca, J. P. Delord, A. Cervantes, B. Markman, J. Corral, J. C. Soria, Y. Bergé, D. Roda, F. Russell-Yarde, et al. 2011. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 29: 3783-3790.